Use of a chlorhexidine-impregnated patch does not decrease the incidence of bacterial colonization of femoral nerve catheters: a randomized trial
Kristopher M Schroeder, Robert A Jacobs, Christopher Guite, Kyle Gassner, Brooke Anderson, Melanie J Donnelly, Kristopher M Schroeder, Robert A Jacobs, Christopher Guite, Kyle Gassner, Brooke Anderson, Melanie J Donnelly
Abstract
Purpose: Femoral nerve catheter (FNC) insertion is commonly performed for postoperative analgesia following total knee arthroplasty (TKA). A wide range of rates has been reported relating to the bacterial colonization of catheters complicating FNC insertion. The BIOPATCH® is a chlorhexidine (CHG) impregnated patch designed to inhibit bacterial growth for days. The BIOPATCH has proven to be effective at decreasing bacterial colonization in epidural and vascular catheters. We hypothesized that the BIOPATCH would be effective at decreasing the rates of FNC bacterial colonization.
Methods: Following Institutional Review Board approval and written informed consent, 100 patients scheduled for TKA were prospectively enrolled in the study. Patients at elevated risk for infection were excluded from analysis. Femoral nerve catheters were inserted and tunneled under sterile conditions using ultrasound guidance following CHG skin cleansing. Participants were then randomized either to have the BIOPATCH applied to the catheter exit site or not to have the patch applied. All patients received pre/postoperative antibiotic therapy. The FNC tip and catheter exit site were cultured for bacterial growth at the conclusion of therapy.
Results: No differences were observed between groups in regards to catheter exit site. Catheter colonization was observed in three of 48 (6.3%) BIOPATCH patients and two of 47 (4.3%) non-BIOPATCH patients (risk ratio [RR] = 1.5; 95% confidence interval [CI] 0.3 to 8.4; P = 1.0). Colonization of the catheter exit site was observed in 12 BIOPATCH and 14 non-BIOPATCH patients (RR = 0.8; 95% CI 0.4 to 1.6; P = 0.65). Local skin inflammation (non-BIOPATCH 10.6% vs BIOPATCH 2.1%) and colonization of the FNC exit site by more than one type of bacteria trended towards increased values in the non-BIOPATCH group.
Conclusions: The baseline rate of bacterial colonization of FNCs is quite low in the setting of short-term use, CHG skin decontamination, ultrasound guidance, subcutaneous tunneling, and perioperative antibiotic therapy. No benefit was shown by using the BIOPATCH in this patient population. (ClinicalTrials.gov number: NCT01411891).
Figures
Source: PubMed
Prochains essais cliniques
-
Nicholas ButowskiSiren BiotechnologyPas encore de recrutementGliome | Tumeur cérébrale | Gliomes récurrents de haut gradeÉtats-Unis
-
State University of New York at BuffaloPas encore de recrutementParticipation des patientsÉtats-Unis
-
Poitiers University HospitalPas encore de recrutement
-
Assistance Publique - Hôpitaux de ParisPas encore de recrutementDrépanocytose | Crise vaso-occlusive
-
University of California, IrvineRecrutementCancer du cerveau | Cancer du SNC | Cancer du système nerveux | Cancer du cerveau métastatiqueÉtats-Unis
-
Qualia Life SciencesRecrutement
-
Guangdong Raynovent Biotech Co., LtdPas encore de recrutement
-
The Hong Kong Polytechnic UniversityWu Jieh Yee Charitable FoundationRecrutementAdultes | Assistance numérique basse vision | Troubles de la visionHong Kong
-
Shanghai General Hospital, Shanghai Jiao Tong University...Pas encore de recrutementAdénocarcinome canalaire pancréatique (PDAC)
-
Sun Yat-sen UniversityPas encore de recrutementSevrage tabagique | Agent IA | Early-Stage Cancer
-
Affiliated Hospital of Nantong UniversityPas encore de recrutement
-
AIMEDBIOBoehringer IngelheimPas encore de recrutementTumeurs solidesFrance, Japon, Corée du Sud, États-Unis, Australie
